

Diffuse Parenchymal Lung Disease

ACOI Board Review 2012

Thomas F. Morley, DO, MACOI, FCCP, FAASM
Professor of Medicine
Chairman Department of Internal Medicine
**Director of the Division of Pulmonary, Critical
Care and Sleep Medicine**
Rowan University - SOM

No Disclosures

Restrictive Lung Diseases

By Category

- 1. Lung Fibrosis**
- 2. Thoracic Deformity**
- 3. Massive effusion**
- 4. Respiratory muscle weakness**
- 5. Increased abdominal pressure**
- 6. Extrinsic Compression**


Mnemonic for Restriction

PAINT

- **Pleural Disease**
- **Alveolar filling**
- **Interstitial**
- **Neuromuscular**
- **Thoracic**

ILD = Misnomer

- **Most of these disease are not restricted to the “interstitium” of the lung**
- **It is actually a radiographic term to differentiate it from alveolar filling diseases**
- **Diffuse Parenchymal Lung Disease is a better term**



The interstitium is the scant space between the capillary endothelial cell and the lung epithelium. It also includes the space that airways, blood vessel, and lymphatics traverse.

Diffuse Parenchymal Lung Disease

Characteristics

- 1. Diffuse infiltrates bilaterally**
- 2. Restrictive Physiology**
- 3. Histologic distortion of gas exchange areas**
- 4. Dyspnea (exercise desat) and cough**

Differential Diagnosis of DPLD

COMMON

Sarcoidosis

**IPF (aka cryptogenic
fibrosing alveolitis**

COP

Lymphangetic Spread of CA

Pneumoconiosis

Drug-induced

Chronic Eosinophilic Pneumonia

LESS COMMON

**Langerhans Cell Histiocytosis
(aka, EG, HX)**

Hypersensitivity Pneumonitis


**Collagen Vascular Diseases
(RA, SLE, MCTD, PSS)**

Granulomatous vasculitis

Goodpasture's syndrome

Alveolar proteinosis

Pathogenesis of Interstitial Lung Diseases



Approach to DPLD

Slide 1

1. Characteristics of Presenting Illness

Duration of Symptoms

Rate of Progression

Fever

Hemoptysis

Extrathoracic manifestations

2. Exposures

Pneumoconiosis

Hypersensitivity

Drug-induced

Occupational

IV drug use

Approach to DPLD

Slide 2

3. Physical Exam	Crackles
Thoracic	Wheeze
	Rub
	Normal
Extrathoracic	Nodes
	Skin
	Joints
	CNS
	Eyes

Approach to DPLD

Slide 3

4. Laboratory (All)

CBC with Diff

UA/Creatinine

CRP, RF, ANA

ACE level

If H+P Suggestive:

**ANCA-c (granulomatosis
with polyangitis)**

RNP (MCTD)

Anti-GBM (Goodpasture's)



Serologic Tests Can Help Exclude Other Conditions

Connective tissue diseases

CRP
ANA
CCP (for RA) Cyclic Citrullinated Peptide Antibody
CK
Aldolase
Anti-myositis panel with Jo-1 antibody
ENA panel

- Scl-70 – SSc (topoisomerase I)
- Ro (SSA) - Sjogrens
- La (SSB)
- Smith -Lupus
- RNP - MCTD

Hypersensitivity pneumonitis

Hypersensitivity panel
(if exposure history)

Approach to DPLD

Slide 4

		Adenopathy	Nodules
5. X-Ray Patterns	Reticular Reticulonodular Nodular Ground Glass	Sarcoidosis Silicosis Berylliosis Langerhans cell granulomatosis	Sarcoidosis Rheumatoid Arthritis Granulomatosis with Polyangitis Sjogren's
Distribution			
Upper Lobe	Silicosis Sarcoidosis Langerhans Cell Gran. Ankylosing spondylitis	Pleural	Asbestos RA SLE
Lower Lobe	IPF Rheumatoid arthritis Asbestosis PSS Sjogren's		

Approach to DPLD

Slide 5

6. PFT	Spirometry Lung volumes DLCO ABG
7. Tissue	Transbronchial Biopsy Thoracoscopy Open lung biopsy Extrathoracic sites
BAL ?	
Gallium Scan ?	

Symptom Duration in DPLD

Chronic	Acute/Subacute
IPF	BOOP/COP
Rheumatoid Lung	Drug-induced
Sarcoidosis	Hypersensitivity
Langerhans Cell Granulomatosis	Chemical exposure
Pneumoconiosis	



Extrathoracic Manifestations of DPLD (1)

Nasal symptoms

Arthritis

Wegener's Granulomatosis

RA

Sarcoidosis

CVD

Sjogren's syndrome

Skin

Sarcoidosis

CVD

Granulomatous vasculitis

Dermatomyositis

PSS

Extrathoracic Manifestations of DPLD (2)

CNS	CVD Sarcoidosis Lymphomatoid granulomatosis
Muscle	Sarcoidosis Polymyositis
GI	PSS Polymyositis
Renal	Granulomatosis with polyangitis CVD Goodpasture's PSS


CASE 1

- 34 y.o. black, female presents with 6 months of non-productive COUGH, and DYSPNEA with exertion**
- NO MEDS or IVDA**
- NO OCCUPATIONAL EXPOSURES**
- NO SYSTEMIC SIGNS OR SYMPTOMS**

Sarcoidosis

X-ray Findings at Presentation


STAGE	FINDINGS	PERCENT
O	Normal	5
I	BHA	50
II	BHA + Lung	30
III	Lung Only	15
IV	Fibrosis	




BHA: Sarcoidosis

**35 yo
male**

Sarcoidosis




***Stage 2 sarcoidosis
pre-tx***



Stage 2 sarcoidosis


2 years post-tx



**Adult
female**

**Nodular
Sarcoidosis**

Stage 3




Sarcoidosis

- **Multisystem disease of unknown etiology
Noncaseating granuloma are characteristic
NOT DIAGNOSTIC**
- **Lung is the most common organ system
involved (94%)**
- **Peak onset 2nd and 3rd decades**
- **10 to 17 times more prevalent in blacks**

Sarcoidosis

- Gallium scan does NOT correlate with need for or response to TX.
- LAB: ACE, LFT's, Calcium, UA hypergammaglobulinemia (68 %)
- Anergy (43 to 66 %)
- Dx: Transbronchial lung biopsy (TBLBx) is adequate for Dx 80 to 90 %.
BAL - lymphocytic
- Tx: Steroids

Noncaseating Granulomas



Diagnosis of Sarcoidosis

THREE ELEMENTS

- 1. Compatible clinical picture**
- 2. Noncaseating granulomas in tissue**
- 3. Negative culture/stains for AFB and fungi**

CASE 2

- 60 y.o. white, male severe exertional dyspnea over 3 to 4 years. Non-productive cough is noted.
- Viral prodrome prior to initial symptoms.
- Nonsmoker, no meds, no occupational exposures, No high risk behaviors
- EXAM - Crackles, digital clubbing

Idiopathic Pulmonary Fibrosis

IPF




Idiopathic Pulmonary Fibrosis ***AKA Cryptogenic Fibrosing Alveolitis***


- Older age (> 60 Y.O.), M sl > F**
- Slow progression over 2 or more years.**
- Non-productive cough, dyspnea**
- Clubbing 50-90 % of patients**

US Demographics of IPF

Incidence



Prevalence



- Incidence: > 30,000 patients/year
- Prevalence: > 80,000 current patients
- Age of onset: most 40–70 years
- Two-thirds > 60 years old at presentation
- Males > females

ATS/ERS. *Am J Respir Crit Care Med.* 2000;161:646-664.

Raghu G, et al. *Am J Respir Crit Care Med.* 2006;174:810-816.

Tx for IPF

50 % mortality at 5 years

10 % develop bronchogenic CA

Nintedanib, (OFEV) a receptor blocker for multiple tyrosine kinases that mediate elaboration of fibrogenic growth factors

Pirfenidone (Espier) is an antifibrotic agent that inhibits transforming growth factor beta (TGF- β)-stimulated collagen synthesis, decreases the extracellular matrix, and blocks fibroblast proliferation in vitro

Transplant


Idiopathic Pulmonary Fibrosis

Diagnosis

- X-ray shows bilateral reticular or reticulonodular infiltrates with lower lobe distribution**
- HRCT -subpleural septal thickening**
- Lab: non-specific**
- Classically Open lung biopsy is required for definitive diagnosis**

Current Definition of IPF

- **Distinct chronic fibrosing interstitial pneumonia**
- **Unknown cause**
- **Limited to the lungs**
- **Has typical HRCT findings**
- **Associated with a histologic pattern of UIP**



ATS/ERS Consensus Statement. *Am J Respir Crit Care Med.* 2002;165:277-304.




School of
Osteopathic Medicine

Diagnostic Criteria for IPF Without a Surgical Lung Biopsy


Major Criteria	Minor Criteria
<ul style="list-style-type: none">• Exclusion of other known causes of ILD	<ul style="list-style-type: none">• Age > 50 years
<ul style="list-style-type: none">• Evidence of restriction and/or impaired gas exchange	<ul style="list-style-type: none">• Insidious onset of otherwise unexplained dyspnea on exertion
<ul style="list-style-type: none">• HRCT: bibasilar reticular abnormalities with minimal ground-glass opacities (honeycombing is characteristic*)	<ul style="list-style-type: none">• Duration of illness > 3 months
<ul style="list-style-type: none">• TBB or BAL that does not support an alternative diagnosis	<ul style="list-style-type: none">• Bibasilar, inspiratory, Velcro® crackles

- All major criteria and at least 3 minor criteria must be present to increase the likelihood of an IPF diagnosis
- Criteria currently under revision (2009)


*Not included in current guidelines
ATS/ERS. *Am J Respir Crit Care Med*. 2000;161:646-664.



IPF - H+E stain




IPF (trichrome stain)



CASE 3

- 43 y.o. white female presented with 2 months of fever, cough, dyspnea, and 12 lbs wt loss
- No meds, 20 P-Y smoker
- No occupational exposures
- No high risk behavior
- Exam: 100 temp, crackles upper lobes

Chronic Eosinophilic Pneumonia



Chronic Eosinophilic Pneumonia



Chronic Eosinophilic Pneumonia

- **Peak 3rd decade, 2:1 F:M**
- **Subacute presentation over months
cough, fever, dyspnea, wt loss**
- **X-ray - bilateral upper lobe infiltrates
PERIPHERAL distribution (esp HRCT)**
- **Blood, biopsy, BAL all with eosinophilia**
- **Dramatic improvement with steroids
(maintain for 6 months)**

Drug-induced Interstitial Lung Disease

Antirheumatics

Gold

Penicillamine

Methotrexate

Antineoplastics

Bleomycin

Cyclophosphamide

Mitomycin

Arrhythmics

Amiodarone

Radiation

Oxygen

Illicit Drugs

Talc

cocaine

Collagen Vascular Diseases with ILD

RA


PSS

Polymyositis/Dermatomyositis

MCTD

LUPUS

**pulmonary
fibrosis
due to
RA**




CASE 4

- 47 y.o. homosexual male with 11 month Hx of non-productive cough, fever, sweats, wheezing**
- Also 35 lbs wt loss over 6 months**
- EXAM: fever, basilar crackles
No clubbing**


**CT
COP (BOOP)**

Subpleural

**Ground
glass
infiltrates**



Cryptogenic Organizing Pneumonia (BOOP)



- Idiopathic
- Viral
- CVD
- Drugs
- Gas
- Transplant
- AIDS

Cryptogenic Organizing Pneumonia

- Patient with patchy alveolar infiltrates who does not improve following antibiotics**
- 4th to 6th decade - subacute 2 -10 wk present**
- Fever, dry cough, following flu-like illness
Myalgia, headache, malaise are common**
- X-ray shows bilateral infiltrates,
10 % reticular
Peripheral distribution on HRCT**

Cryptogenic Organizing Pneumonia

- Pathology**
Intraluminal fibrosis with connective tissue plugs in the respiratory bronchioles, alveolar ducts, and alveoli
- Open lung Bx - NOT NECESSARY**
TBLBx and BAL are adequate
- Steroid Responsive**
3 to 6 months Tx
Recurrence common if Tx stopped too early

CASE 5

- 53 y.o. white male progressive dyspnea over 1 year. Some cough with yellow Sputum**
- Heavy Smoker**
- Occupation: tombstones engraver**
- EXAM: decreased breath sounds digital clubbing**

56 yo
Male

Anthracosis
PMF




56 yo
Male

Anthracosis
PMF



School of
Osteopathic Medicine

Silicosis, PMF, Cavitation





School of
Osteopathic Medicine

Egg shell calcification




Pneumoconiosis

Inhaled Inorganic Dusts

- 1. Big Three
Asbestosis, Anthracosis, Silicosis**
- 2. Long gap between exposure and symptoms
from ILD**
- 3. Asbestos - Lower lobe reticular changes
Parietal pleural plaques**
- 4. Anthracosis - Upper lobe nodules - PMF**
- 5. Silicosis - Upper lobe nodules - PMF
Hilar adenopathy
Egg shell calcification**

Asbestos plaques





TY

c Medicine


Hypersensitivity Pneumonitis

- * Caused by repeated inhalation of an ORGANIC dust or chemical - leads to sensitization**
- * Symptoms may be acute or chronic**
- * Fever, cough, dyspnea, and infiltrates occur 4 to 6 hrs post exposure
Repeated exposure leads to fibrosis**
- * Dx: depends on history and specific precipitating antibodies to the antigen**

Hypersensitivity Pneumonitis

- * **Type III - immune complex injury and Type IV - delayed hypersensitivity is involved in pathology**
- * **Acute pathology shows PMN infiltrate 3 days later the infiltrate becomes lymphocytic and loose granulomas form. FOAMY histiocytes and bronchiolitis obliterans may be noted**

Hypersensitivity Pneumonitis




Langerhans Cell Histiocytosis

EG, HSC, and LS

- All 3 disorders share a common pathology (These terms have been abandoned).
- ✓ Aggregations of abnormal histiocytes (Langerhans's cells)
- Lung and bone are most often affected with UNIFOCAL disease
- Multifocal disease - worse prognosis

**26 yo
male**

**Langerhans
Cell
Histiocytosis**




26 yo
male

LCH



*Langerhans
Cell
Histiocytosis*



LCH

CLINICAL FEATURES

- 10 to 40 Y.O. M=F**
- Present with cough, fever, dyspnea, chest pain**
- 10 % present with pneumothorax**
- X-ray - upper lobe cystic and reticulonodular changes
NO VOLUME LOSS**